Cimetidine use and risk of breast, prostate, and other cancers

Pharmacoepidemiology and Drug Safety

Volumn 9, Issue 2, 2000, Pages 149-155

  Habel, Laurel A ^a,b   Levin, Theodore R ^b   Friedman, Gary D ^a  

^a DIVISION OF RESEARCH   (United States)

^b NONE

Author keywords

Cancer; Cimetidine; Histamine 2 receptor antagonists; Incidence; Risk factors

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CIMETIDINE; ESTRADIOL; NON PRESCRIPTION DRUG; RANITIDINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; COLON CANCER; CONTROLLED STUDY; DATA BASE; DRUG MONITORING; DRUG USE; ESOPHAGUS CANCER; FEMALE; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYELOMA; OVARY CANCER; PANCREAS CANCER; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; RECTUM CANCER; REGRESSION ANALYSIS; STOMACH CANCER; UNITED STATES; UTERUS CANCER;

EID: 0034029533     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(200003/04)9:2<149::AID-PDS481>3.0.CO;2-1     Document Type: Article

References (19)

1. Knight E. PDS national prescription and sales audit July 1987-1988. Pharmaceutical Data Services: Scottsdale, Arizona, 1988.
2. Brunton LL. Agents for control of gastric acidity and treatment of peptic ulcers. In Goodman & Gillman's The Pharmacologic Basis of Therapeutics, (9th edn), Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, (eds). McGraw-Hill: New York, 1996: 904-907.
3. Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. N Engl J Med 1990; 323: 1672-1680.
4. Galbriath RA, Michnovicz JJ. The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med 1989; 321: 269-274.
5. Michnovicz JJ, Galbraith RA. Cimetidine inhibits catechol estrogen metabolism in women. Metabolism 1991; 40: 170-174.
6. Stolinksy DC. Prostate cancer and histamine2 antagonists. J Natl Cancer Inst 1991; 83: 1589.
7. Moller H, Lindvig K, Klefter R, Mosbech J, Moller Jensen O. Cancer occurrence in a cohort of patients treated with cimetidine. Gut 1989; 30: 1558-1562.
8. Collin-Jones DG, Langman MJS, Lawson DH, Logan RFA, Paterson KR, Vessey MP. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. Gut 1992; 33: 1280-1284.
9. Moller H, Mellemgaard A. Prostate cancer incidence in cimetidine users. J Natl Cancer Inst 1992; 84:359-360.
10. Kahn HA, Sempos CT. Statistical methods in epidemiology. In Monographs in Epidemiology and Biostatistics, MacMahan B. (ed). Oxford University Press: New York, 1989; 193-198.
11. Johnson ERG, Jick SS, Perera DR, Jick H. Histamine-2 antagonists and gastric cancer. Epidemiology 1996; 7: 434-436.
12. Baron JA, Rohan TE. Tobacco. In Cancer Epidemiology and Prevention (2nd edn), Schottenfeld D, Fraumeni Jr JF. (eds). Oxford University Press: New York, 1996; 269-289.
13. Everhart JE, Byrd-Holt D, Sonnenberg A. Incidence and risk factors for self-reported peptic ulcer disease in the United States. Am J Epidemiol 1998; 147(6): 529-536.
14. Martucci CP, Fishman J. Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology 1979; 105: 1288-1292.
15. Schneider J, Huh MM, Bradlow HL, Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 1984; 259: 4840-4845.
16. Schneider J, Kinne D, Fracchia A et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 1982; 79: 3047-3051.
17. Lemon HM, Heidel JW, Rodriguez-Sierra JF. Increased catechol estrogen metabolism as a risk factor for nonfamilial breast cancer. Cancer 1992; 69: 457-465.
18. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993; 15: 48-65.
19. Ross RK, Schottenfeld D. Prostate cancer. In Cancer Epidemiology and Prevention, (2nd edn), Schottenfeld D, Fraumeni Jr JF, (eds). Oxford University Press: New York, 1996; 1180-1206.